Analysts name 2 ASX growth shares to buy

These growth shares could be in the buy zone…

| More on:
Investor riding a rocket blasting off over a share price chart

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Fortunately for growth investors, there are plenty of shares on the Australian share market with strong long term growth potential.

Two such shares are named below. Here's why analysts are positive on them:

ResMed Inc. (ASX: RMD)

The first ASX growth share to consider is ResMed. It is focused on the development, manufacturing, distribution, and marketing of medical devices and cloud-based software applications that diagnose, treat and manage respiratory disorders.

ResMed's product support suffers of sleep disordered breathing (SDB), chronic obstructive pulmonary disease (COPD), neuromuscular disease, and other chronic diseases.

Thanks to its world class portfolio, huge (and growing) market opportunity, and wide distribution network, ResMed appears well-placed for growth again over the 2020s. Particularly given a major product recall from a key rival.

Morgans is very positive on ResMed. It believes "the company remains well-placed as it builds a unique, patient-centric, connected-care digital platform that addresses the main pinch points across the healthcare value chain."

Its analysts currently have an add rating and $40.46 price target on its shares. This is notably higher than the current ResMed share price of $31.83.

Xero Limited (ASX: XRO)

Another ASX growth share to look at is Xero. It is a provider of a cloud-based business and accounting solution to small and medium sized businesses.

Xero has been growing strongly for many years and looks well-placed to continue this trend in the future. This is thanks to its ongoing international expansion, value accretive acquisitions, the transition to the cloud, and its burgeoning app ecosystem. The latter has significant monetisation potential according to the team at Goldman Sachs.

Goldman believes the app ecosystem could support Xero's ARPU growth in the coming years. Which, combined with subscriber growth, is expected to underpin strong revenue growth over the 2020s.

The broker currently has a buy rating and $158.00 price target on its shares. This compares to the latest Xero share price of $101.67.

Motley Fool contributor James Mickleboro has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. owns and has recommended Xero. The Motley Fool Australia owns and has recommended Xero. The Motley Fool Australia has recommended ResMed Inc. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

More on Growth Shares

Person pointing at an increasing blue graph which represents a rising share price.
Growth Shares

2 ASX growth shares to snap up while they're still down

Brokers see plenty of upside for these mainstay sector picks.

Read more »

Man pointing an upward line on a bar graph symbolising a rising share price.
Growth Shares

Why these ASX growth stocks could be much bigger in 2030 than today

These stocks have long growth runways and strong business models.

Read more »

A woman sits at her computer with her hand to her mouth and a contemplative smile on her face as she reads about the performance of Allkem shares on her computer
Growth Shares

3 incredible ASX growth shares to buy and hold forever in 2026

True long-term investing means owning businesses you’d be happy to hold through volatility, uncertainty, and decades of change.

Read more »

Happy work colleagues give each other a fist pump.
Growth Shares

2 shares to buy hand over fist before the ASX 200 soars higher in 2026

These shares are highly rated by brokers for a reason. Here's what you need to know about them.

Read more »

Buy now written on a red key with a shopping trolley on an Apple keyboard.
Broker Notes

Experts rate these 2 ASX shares as buys this month!

Leading analysts say these stocks are a buy.

Read more »

Happy healthcare workers in a labs
Technology Shares

Prediction: CSL shares could soar past $270 in 2026

Here's what to expect from the Australian-based global biotechnology company this year.

Read more »

A bearded man holds both arms up diagonally and points with his index fingers to the sky with a thrilled look on his face over these rising Tassal share price
Growth Shares

2 unstoppable ASX 200 stocks to buy in 2026 and hold forever

These blue chips could have very bright futures. Do you own them?

Read more »

A man sees some good news on his phone and gives a little cheer.
Growth Shares

5 incredible ASX growth stocks to buy for 2026

These growth stocks could be well-positioned for the long-term.

Read more »